MT2A

Across TCGA pan-cancer cohorts, MT2A RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MT2A’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where MT2A RNA is repressed in tumor relative to normal tissue. In most cancer types MT2A is over-expressed in tumor, although a few such as COAD and LIHC show the opposite, repressed pattern.

COAD, LIHC, and KICH are the cancer types where MT2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MT2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	−2.524	<.001	11	view →
LIHC	Female	II,III,IV	−4.368	<.001	9	view →
KICH	Female	All	−2.317	<.001	8	view →
BRCA	Female	II,III,IV	−0.694	<.001	6	view →
CHOL	All	All	−3.503	<.001	5	view →
HNSC	Female	IV	+1.223	.005	5	view →
LUSC	All	II,III,IV	−1.187	.002	5	view →
KIRP	All	All	−1.698	<.001	4	view →
THCA	Male	All	−0.560	.015	3	view →
READ	Female	All	−2.513	<.001	2	view →
LUAD	All	All	−0.627	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MT2A–COAD

Open the COAD breakdown →